GlassScriptPhysician profile
Stacey E Mullin
NPI 1659831642
$4,789.81
in general payments reported to CMS, 2019-2025
39 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $798 · 2022: $1,065 · 2023: $523 · 2024: $550 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $519.12 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $511.43 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $411.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $314.19 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $282.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $278.70 | 2022-2025 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $237.79 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $187.82 | 2021-2025 | |
| Amgen INC. | $163.42 | 2021-2024 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $154.54 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.15 | 2021-2023 | Ofev, Jardiance |
| Xeris Pharmaceuticals, INC. | $129.20 | 2021-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $76.12 | 2021-2022 | |
| Axsome Therapeutics, INC. | $71.21 | 2025 | Auvelity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Mullin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.